总投资5.1亿！虹摹生物，落地合肥高新区

Core Insights - The article discusses the establishment of a synthetic biology project by Hongmo Biotechnology in Hefei High-tech Zone, with a total investment of approximately 510 million yuan, aimed at producing human milk oligosaccharides (HMOs) [2][4]. Group 1: Project Overview - Hongmo Biotechnology signed a landing agreement with Hefei High-tech Zone on February 4, marking the official establishment of a synthetic biology project [2]. - The project will occupy 50 acres and will be developed in two phases, with an expected annual production capacity of 3,000 tons and an estimated annual output value of 1.5 billion yuan upon full production [2]. Group 2: Company Background - Hongmo Biotechnology, incubated by Mengniu Group, focuses on the independent research and industrialization of HMOs, aiming to break the long-standing international monopoly in this field [4]. - The company is the first and only in China to have received health commission approval for three HMO products: 2'-fucosyllactose (2'-FL), lacto-N-neotetraose (LNnT), and 3'-sialyllactose sodium salt (3'-SL) [4]. Group 3: Industry Context - Hefei High-tech Zone has actively positioned itself in the synthetic biology industry, currently hosting around 30 related enterprises, including Kasei Biotech, and has established a comprehensive innovation system from basic research to industrialization [4]. - The zone aims to enhance its industrial ecosystem through targeted policies and collaborative industry funds, focusing on attracting key enterprises and projects in the synthetic biology supply chain [4].